Zonisamide, a sulfonamide analogue, has been recently approved in Europe and the United States as an adjunctive therapy for patients with partial-onset epilepsy. Several studies have supported its potential role in managing compulsive behaviors such as binge-eating disorders, obesity, and ICDs associated with Parkinson disease. In our study, doses of zonisamide ranging from 100 to 150 mg/d achieved a good clinical response with minimal adverse effects.

Although our results were obtained in an open treatment protocol and included a small number of subjects, the significant reduction in psychologic and skin symptoms suggests that zonisamide should be subjected to investigation in controlled trials for treatment of ICDs in skin diseases.

Maria Jose Tribo, MD, PhD Eduardo Alejandro Rozas-Muñoz, MD Fernando Gallardo, MD, PhD Noemí Casanova, MD Salvador Ros-Montalban, MD, PhD Antoni Bulbena, MD, PhD Ramon Pujol, MD, PhD

Financial Disclosure: None reported.

Accepted for Publication: December 20, 2012.

Author Affiliations: Departments of Dermatology (Drs Tribo, Rozas-Muñoz, Gallardo, and Pujol), Psychiatry (Dr Casanova, Ros-Montalban, and Bulbena), and Psychology (Dr Casanova), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain.

Correspondence: Dr Tribo, Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain, Passeig Marítim 25-29, 08003 Barcelona, Spain (mjtribo@gmail.com).

Author Contributions: All authors had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Tribo. Acquisition of data: Tribo, Rozas-Muñoz, Gallardo, Casanova, and Pujol. Analysis and interpretation of data: Tribo, Casanova, Ros-Montalban, and Bulbena. Drafting of the manuscript: Tribo and Rozas-Muñoz. Critical revision of the manuscript for important intellectual content: Tribo, Gallardo, Casanova, Ros-Montalban, Bulbena, and Pujol. Statistical analysis: Tribo and Rozas-Muñoz. Administrative, technical, and material support: Casanova. Study supervision: Tribo, Gallardo, Ros-Montalban, Bulbena, and Pujol.

Sebum Transforming Growth Factor β1 Induced by Hair Products

Chemical hair processing is used by more than 60% of women with Afro-textured hair and is a suspected contributor to scarring alopecia. We recently reported changes in 6 proinflammatory cytokines on scalp sebum of 36 women. Baseline scalp interleukin (IL)-1α in all participants including those with natural hair was higher than expected (ie, 18 times IL-1α levels), which may suggest a predisposition to scalp inflammation. However, there was no difference in levels of IL-1α when sebum from shampooed natural hair was compared with that treated with ammonium thioglycolate (permanent wave), sodium hydroxide (“lye”) and guanidine hydroxide (“no-lye”) relaxers. Changes in IL-1α were significant on the vertex but not on the crown, which may suggest site-specific scalp predisposition to inflammation.

Methods. In this study, samples from 36 participants (12 natural, 24 chemically treated) were tested for the presence of the profibrotic cytokine transforming growth factor (TGF)-β1. The original study1 was conducted at Groote Schuur Hospital in 2010 and approved by the faculty ethics committee. Sebum was collected by applying Sebutape (CutDerma Corporation) to the scalp crown and vertex at visit 1 (before and after scalp shampoo), visit 2 (before and after chemical treatments), and on follow-up (visit 3). Details of chemical hair treatments and sample preparation for detection of cytokines have been described previously. Concentrations of TGF-β1 were determined using the Quantikine Human TGF-β1 Immunoassay (R&D Systems) according to the manufacturer’s instructions.

Data analyses were performed using Stata software, version 12 (StataCorp LP).

Comparisons of interest were TGF-β1 levels with anatomic site after various chemical treatments and on follow-up. These comparisons were performed using Pearson χ² Fisher exact tests. Statistical significance was defined at the 5% alpha level (P = .05) for a 2-tailed hypothesis test.

Results. There was a significant difference (P = .02) in the age of participants with a positive TGF-β1 finding (Table), all detected in samples taken after shampoo or chemical treatment. Only 1 sample from natural hair tested positive for TGF-β1; this was after shampoo treatment. All samples that tested positive at visit 3 (when no shampoo or chemical treatment occurred) were previously chemically treated. Two participants had positive TGF-β1 test results (the first tested positive at both scalp sites on visit 1; the second had higher TGF-β1 levels detected on natural hair at visit 1 than on follow-up after treatment with a lye relaxer); a third participant had 3 detectable TGF-β1 levels on 2 visits.

The number of participants with chemically treated hair was double that with natural hair. Overall, 16 samples (from 12 participants) yielded a positive TGF-β1 result; all except 1 of these were from chemically treated (94%) vs (6%) natural hair (Table). However, there was no statistically significant difference in detected TGF-β1 lev-
The detection of TGF-β1 had occurred predominantly in chemically altered hair but was inconsistent and lacked statistically significant difference in levels compared with findings in natural hair or between scalp sites. Large studies that correlate sebum cytokine levels and histologic characteristics may elucidate the association between hair chemical use and scarring alopecia.

**Accepted for Publication:** December 6, 2011.

**Author Affiliations:** Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada (Dr Beach); Institute of Infectious Disease and Molecular Medicine (Dr Wilkinson), Department of Statistical Sciences (Dr Gumedze), Division of Dermatology, Groote Schuur and Red Cross Children’s Hospitals (Dr Khumalo), University of Cape Town, Cape Town, South Africa.

**Correspondence:** Dr Khumalo, Division of Dermatology, Ward G23, New Groote Schuur Hospital, Observatory 7925, Cape Town, South Africa (n.khumalo@uct.ac.za).

**Author Contributions:** Dr Khumalo had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Khumalo. Acquisition of data: Beach, Wilkinson, and Khumalo. Analysis and interpretation of data: Beach, Wilkinson, Gumedze, and Khumalo. Drafting of the manuscript: Beach and Khumalo. Critical revision of the manuscript for important intellectual content: Wilkinson, Gumedze, and Khumalo. Statistical analy-
Induced Lentiginosis With Use of Topical Calcineurin Inhibitors

Acquired lentiginosis at sites of inflammatory skin disease may occur at the sites where topical tacrolimus or pimecrolimus was applied.1

Methods. Patients who developed acquired lentiginosis at sites of long-term use of topical tacrolimus ointment or pimecrolimus cream were identified by retrospective chart review. Age at onset of lentigines, duration of exposure to topical tacrolimus and pimecrolimus, and time to regression were recorded. Biopsies were performed in 2 of 12 patients, and specimens showed increased numbers of epidermal melanocytes and mild pigment incontinence consistent with the diagnosis of lentigo. Approval by the institutional review board was waived.

Results. The anatomic sites involved in our 12 patients included the relatively sun-protected areas of the antecubital fossa, dorsal hands, popliteal fossa, and wrists with chronic dermatitis (Figure 1 and Figure 2). Patients with atopic dermatitis (8 of 12), psoriasis (2 of 12), Netherton syndrome (1 of 12), and perioral dermatitis (1 of 12).